|
 The recommendation follows comments from the health regulator's
staff on Tuesday on likely errors in administering the experimental
drug.
The agency's staff on Wednesday had also highlighted that a rival
opioid painkiller from Collegium Pharmaceuticals Inc could be
wrongly used.
Collegium's shares were down 18 percent at $11.06 in extended
trading.
An FDA panel is expected to review Collegium's experimental drug on
Friday.
Purdue Pharma's experimental drug, to be called Avridi on approval,
was designed as an abuse-deterrent fast-acting form of opioid
painkiller oxycodone.
The FDA panel voted 23 to 1 against the approval.
Avridi is among the first few drugs to be evaluated by the FDA for
the efficacy of such formulations' abuse-deterrent properties.
An estimated 46 people die everyday in the United States from opioid
painkiller overdose, according to The Centers for Disease Control
and Prevention.
[to top of second column] |
Avridi is designed to be taken every 4-6 hours on an empty stomach
and the presence of food could cause inadequate pain control.
Inadequate pain control could lead to patients taking more of the
drug, the FDA staff had said.
Most painkillers can be administered irrespective of food intake.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
